Testing Efficacy Or Toxicity Of A Compound Or Composition (e.g., Drug, Vaccine, Etc.) Patents (Class 424/9.2)
  • Patent number: 11366102
    Abstract: A method of predicting the responsiveness of a patient to a pharmaceutical drug by measuring metabolites in a biological sample from the patient is disclosed. Specific drug metabolites in blood from breast cancer patients are analyzed using NMR spectroscopy whereby responsiveness of the human cancer patients before, during and after treatment with a cancer drug is assessed by measuring the change in clinical outcomes. Data obtained is used to identify particular NMR resonances that are strongly correlated with whether the patient is responsive or resistant to each drug. As such, models for predicting the responsiveness of a patient to each drug based on metabolites from the patient are provided.
    Type: Grant
    Filed: October 9, 2019
    Date of Patent: June 21, 2022
    Assignee: Olaris, Inc.
    Inventors: Elizabeth M. O'Day, Chen Dong, Bo Zhang, Srihari Raghavendra Rao
  • Patent number: 11274290
    Abstract: Methods of enhancing biomass and secondary metabolite accumulation of microalgal species are described herein. A cell culture of the microalgal species were elicited using a combination of techniques for a period of time. Experimental studies compared biomass dry weight production, chlorophyll dry weight content and astaxanthin dry weight content between controls and elicitation treatments. The present invention demonstrated that combined elicitation is an effective method for improving cell biomass growth and astaxanthin production.
    Type: Grant
    Filed: November 18, 2019
    Date of Patent: March 15, 2022
    Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA
    Inventors: Joel L. Cuello, Chen-Han Shih
  • Patent number: 11235014
    Abstract: Provided herein are custom therapeutic compositions combining select Chinese herbs and strains of Cannabis, methods of making the compositions, and methods of using the composition for treatment of headache pain.
    Type: Grant
    Filed: April 10, 2020
    Date of Patent: February 1, 2022
    Inventor: Artashes Mirzatuny
  • Patent number: 11213581
    Abstract: The present disclosure provides recombinantly manufactured fusion proteins comprising a SARS-CoV-2 Receptor Binding Domain (SARS-CoV-2-RBD) fragment or an analog thereof linked to a human Fc fragment for use in relation to the 2019 Novel Coronavirus (COVID-19). Embodiments include the administration of the fusion proteins to patients that have recovered from COVID-19 as a booster vaccination, to antibody naïve patients to produce antibodies to the SARS-CoV-2 virus to enable the patients to become convalescent plasma donors, to patients who have been infected by the SARS-CoV-2 virus and have contracted COVID-19 in order to limit the scope of the infection and ameliorate the disease, and as a prophylactic COVID-19 vaccine. Exemplary Fc fusion proteins and pharmaceutical formulations of exemplary Fc fusion proteins are provided, in addition to methods of use and preparation.
    Type: Grant
    Filed: April 9, 2021
    Date of Patent: January 4, 2022
    Assignee: Akston Biosciences Corporation
    Inventors: Todd C. Zion, Thomas M. Lancaster, Thillainayagam Sathiyaseelan, Kexin Huang
  • Patent number: 11207401
    Abstract: The invention relates to pharmaceutical compositions that contain COVID-19 peptide specific cytotoxic T cells, and to methods for treating or preventing COVID-19 infection.
    Type: Grant
    Filed: May 7, 2021
    Date of Patent: December 28, 2021
    Assignee: Tevogen Bio Inc.
    Inventor: Ryan Saadi
  • Patent number: 11179439
    Abstract: Provided herein are methods and compositions for preventing and treating damage to the heart subsequent to myocardial infarction (MI) resulting from harmful fibrotic remodeling, thereby improving cardiac function and reducing mortality from subsequent heart failure.
    Type: Grant
    Filed: June 18, 2019
    Date of Patent: November 23, 2021
    Assignees: MandalMed, Inc., The Regents of the University of California
    Inventors: Constance M. John, Meenakshi Gaur, Matthew L. Springer, Xiaoyin Wang
  • Patent number: 11179395
    Abstract: Provided herein are methods for treating melanoma in a subject.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: November 23, 2021
    Assignee: GEORGETOWN UNIVERSITY
    Inventors: Sivanesan Dakshanamurthy, Stephen W. Byers, Dean Rosenthal
  • Patent number: 11173218
    Abstract: Biocompatible polymeric nanoparticles may include: a biocompatible polymer and/or functional metal nanostructures. The biocompatible polymer may be a polyhydroxyalkanoate (PHA). The functional metal nanostructures may include at least one noble metal, at least one magnetic metal oxide, or mixtures thereof. The biocompatible polymeric nanoparticles may have an average size less than or equal to 200 nanometers (nm).
    Type: Grant
    Filed: June 27, 2017
    Date of Patent: November 16, 2021
    Assignee: BIO-ON S.P.A.
    Inventor: Mauro Comes Franchini
  • Patent number: 11130798
    Abstract: Provided herein are composition comprising novel epitopes of ApoB100, as well as sub-sequences, portions and modifications thereof, and uses thereof for treating adverse cardiovascular events, cardiovascular disease, atherosclerosis and certain liver disorders.
    Type: Grant
    Filed: May 18, 2016
    Date of Patent: September 28, 2021
    Assignee: LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY
    Inventors: Klaus Ley, Alessandro Sette
  • Patent number: 11104723
    Abstract: Provided herein are methods and compositions for disrupting biofilms in vitro and in vivo. Also disclosed are antibodies comprising a specified heavy chain (HC) immunoglobulin variable domain sequence and/or a specified light chain (LC) immunoglobulin variable domain sequence.
    Type: Grant
    Filed: January 28, 2021
    Date of Patent: August 31, 2021
    Assignee: RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL
    Inventors: Steven D. Goodman, Lauren O. Bakaletz
  • Patent number: 11077214
    Abstract: The present application relates to compositions comprising an iodinated contrast agent and indocyanine green co-encapsulated inside a liposomal carrier, various uses thereof as well as methods for their preparation.
    Type: Grant
    Filed: May 26, 2014
    Date of Patent: August 3, 2021
    Assignee: University Health Network
    Inventors: Jinzi Zheng, David A. Jaffray, Christine Allen
  • Patent number: 11037686
    Abstract: An information processing apparatus, an information processing method, and an information processing program which are capable of suppressing an increase in consumption of system resources used for suppressing a spread of an infection disease are acquired. An information processing apparatus includes an acquisition unit that acquires information regarding an infection disease of a first animal infected with the infection disease, a specification unit that specifies a second animal positioned within a behavior area of the first animal, a determination unit that determines whether or not the infection disease of the first animal is likely to infect the second animal, and a notification unit that notifies an owner of the second animal of an alarm regarding the infection disease in a case where it is determined that the infection disease of the first animal is likely to infect the second animal.
    Type: Grant
    Filed: January 8, 2020
    Date of Patent: June 15, 2021
    Assignee: FUJIFILM CORPORATION
    Inventors: Shigetoshi Ishikawa, Yasuhisa Kaneko, Haruyasu Nakatsugawa
  • Patent number: 11006892
    Abstract: The invention relates to a device for assessing the characteristics of the swallowing process in a subject a sensor that is capable of detecting vibrations of the throat during swallowing.
    Type: Grant
    Filed: March 19, 2015
    Date of Patent: May 18, 2021
    Assignee: Societe des Produits Neslte S.A.
    Inventors: Michael Jedwab, Adam Burbidge
  • Patent number: 11009576
    Abstract: Described here are systems and methods for volumetric excitation in magnetic resonance imaging (“MRI”) using frequency modulated radio frequency (“RF”) pulses. In general, quadratic phase modulation along the slice encoding direction is implemented for additional spatiotemporal encoding, which better distributes signal content in the slice direction and enables higher acceleration rates that are robust to slice-undersampling.
    Type: Grant
    Filed: April 6, 2018
    Date of Patent: May 18, 2021
    Assignee: Regents of the University of Minnesota
    Inventors: Steen Moeller, Mehmet Akcakaya
  • Patent number: 10975127
    Abstract: The present invention relates to, in part, compositions comprising improved flagellin derived constructs and methods of using for vaccination, including adjuvants comprising flagellin-based agents.
    Type: Grant
    Filed: June 24, 2020
    Date of Patent: April 13, 2021
    Assignee: Genome Protection, Inc.
    Inventors: Andrei V. Gudkov, Vadim Mett, Vadim Krivokrysenko
  • Patent number: 10935543
    Abstract: The present invention relates to a method for determining a level of fat-free body mass (FFM) in a paediatric subject comprising determining a level of phenylacetylglutamine (PAG) in a sample obtained from the subject.
    Type: Grant
    Filed: December 30, 2016
    Date of Patent: March 2, 2021
    Assignee: Societe des Produits Nestle S.A.
    Inventors: François-Pierre Martin, Omella Cominetti, Jean-Philippe Godin, Jessica Ezri, Andreas Nydegger
  • Patent number: 10918673
    Abstract: Provided herein is technology relating to immunoisolation of cells and tissues, including, but not exclusively, to compositions, methods, and kits for encapsulating cells and/or tissues within an immunoisolating device to protect the cells/or tissues from host immune rejection.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: February 16, 2021
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventor: Ariella Shikanov
  • Patent number: 10914734
    Abstract: Compositions which comprise a gold nanoparticle, dithiolated diethylenetriamine pentaacetic acid (DTDTPA), and a thioctic acid terminated peptide, wherein the DTDTPA is directly linked to the gold nanoparticle surface via an Au—S bond, and wherein the thioctic acid terminated peptide is directly linked to the gold nanoparticle surface via an Au—S bond.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: February 9, 2021
    Assignee: The Curators of the University of Missouri
    Inventors: Raghuraman Kannan, Ajit Zambre, Anandhi Upendran
  • Patent number: 10912456
    Abstract: A system, method and computer program product for estimating future axial elongation of an individual's eye as a way to predict and track refractive error progression of an individual. The method includes: receiving, via a computer interface, data relating to refractive change in a prior pre-determined time period for the individual from a reference timepoint; receiving data representing an age of the individual and data representing a current axial length value of the eye as measured at the reference timepoint; calculating, by said processor, a future axial elongation of the eye as a function of the age of the individual, the current axial length value of the eye as measured at the reference timepoint, and the refractive change in the prior pre-determined time period; generating, an output indication of said computed axial elongation of the eye, and using said output indication to select a myopia control treatment for said individual.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: February 9, 2021
    Assignee: Johnson & Johnson Vision Care, Inc.
    Inventors: Noel A. Brennan, Xu Cheng
  • Patent number: 10912790
    Abstract: The invention relates to saRNA targeting a C/EBP? transcript and therapeutic compositions comprising said saRNA. Methods of using the therapeutic compositions are also provided.
    Type: Grant
    Filed: April 21, 2016
    Date of Patent: February 9, 2021
    Assignee: MiNA THERAPEUTICS LIMITED
    Inventors: Andreas Wagner, Robert Habib, Hans E. Huber, Pål Sætrom, Endre Bakken Stovner, Markus Hossbach, Monika Krampert, Hans-Peter Vornlocher
  • Patent number: 10880378
    Abstract: One embodiment provides a method, including: receiving, at an information handling device, an indication to initiate a contextual session associated with a context; receiving, at the device, at least one context input during a duration of the contextual session; and responsive to receiving the at least one context input, extending the duration of the contextual session, wherein the extended duration does not require receipt of subsequent indications. Other aspects are described and claimed.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: December 29, 2020
    Assignee: Lenovo (Singapore) Pte. Ltd.
    Inventors: Russell Speight VanBlon, Arnold S. Weksler, John Carl Mese, Nathan J. Peterson
  • Patent number: 10801028
    Abstract: An isolated nucleic acid agent is disclosed comprising a nucleic acid sequence which downregulates expression of a gene product of a Varroa destructor mite. Compositions comprising same and uses thereof are also disclosed.
    Type: Grant
    Filed: April 26, 2017
    Date of Patent: October 13, 2020
    Assignees: BEEOLOGICS INC., YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
    Inventors: Ilan Sela, Sharoni Shafir, Eyal Maori, Yael Garbian, Eyal Ben-Chanoch, Gal Yarden, Haim Kalev
  • Patent number: 10759733
    Abstract: The present disclosure provides treprostinil derivatives that can act as prodrugs of treprostinil. The treprostinil derivatives can be used to treat any conditions responsive to treatment with treprostinil, including pulmonary hypertension, such as pulmonary arterial hypertension.
    Type: Grant
    Filed: September 24, 2019
    Date of Patent: September 1, 2020
    Assignee: Corsair Pharma, Inc.
    Inventors: Xiaoming Zhang, Meenakshi S. Venkatraman, Cyrus K. Becker
  • Patent number: 10758602
    Abstract: The present invention relates to an immunogenic composition comprising: a) one or more antigen of M. hyorhinis and one or more antigens of M. hyosynoviae; and b) a pharmaceutically acceptable carrier. Furthermore, the present invention relates to an immunogenic composition that comprises a) one or more mycoplasma antigens of mycoplasma bacteria selected from the group consisting of M. hyorhinis, M. hyopneumoniae and M. hyosynoviae; and b) one or more components of a eukaryotic cell system. Moreover, the present invention also provides an immunogenic composition obtained by a method comprising a) cultivation of a mycoplasma bacteria selected from the group consisting of M. hyorhinis, M. hyopneumoniae and M. hyosynoviae in a serum-reduced, eukaryotic cell system; b) obtaining an antigen of such mycoplasma bacteria; and c) addition of a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: September 1, 2020
    Inventors: Dianna M. Murphy Jordan, Brian Thomas Martinson, Christine Margaret Muehlenthaler, Axel Neubauer, Arun V. Iyer
  • Patent number: 10744213
    Abstract: The present invention discloses fluorescent compounds and a method for their use for selective imaging of blood vessels and blood flow. By applying these fluorescent compounds and the imaging process to a zebrafish model, the present invention further provides methods and procedures for the discovery, selection, and characterization of pro- and anti-angiogenic agents.
    Type: Grant
    Filed: February 14, 2017
    Date of Patent: August 18, 2020
    Assignee: COLOSSUS BIOPHARMA CONSULTANTS COMPANY, LIMITED
    Inventor: Jose Mendoza
  • Patent number: 10730915
    Abstract: The present invention relates to, in part, compositions comprising improved flagellin derived constructs and methods of using for vaccination, including adjuvants comprising flagellin-based agents.
    Type: Grant
    Filed: May 16, 2019
    Date of Patent: August 4, 2020
    Assignee: Genome Protection, Inc.
    Inventors: Andrei V. Gudkov, Vadim Mett, Vadim Krivokrysenko
  • Patent number: 10724101
    Abstract: The present invention provides a method for diagnosing and determining prognosis of gastric cancer in a subject by detecting suppressed expression of the SCNN1B gene, which in some cases is due to elevated methylation level in the genomic sequence of this gene. A kit and device useful for such a method are also provided. In addition, the present invention provides a method for treating gastric cancer by increasing SCNN1B gene expression or activity.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: July 28, 2020
    Assignee: The Chinese University of Hong Kong
    Inventors: Jun Yu, Joseph Jao Yiu Sung, Chi Chun Wong
  • Patent number: 10711043
    Abstract: The disclosure relates to compositions, pharmaceutical compositions, vaccines, and methods of making and using the same. The compositions of the disclosure are useful to stimulate an antigen-specific immune response and, in some embodiments, a protective immune response in an animal after challenge to pathogens. The compositions of the disclosure are also useful for treatment and prevention of disease in a subject such as cancer.
    Type: Grant
    Filed: July 9, 2018
    Date of Patent: July 14, 2020
    Assignees: University of Maryland, College Park, University of Maryland, Baltimore
    Inventors: Philip R. DeShong, Lenea Stocker, Daniel C. Stein, Stefanie N. Vogel, Katharina Richard
  • Patent number: 10682408
    Abstract: Embodiments described herein relate to restorative solutions for segmental peripheral nerve (PN) defects using allografted PNs for stimulating PN repair. More specifically, embodiments described herein provide for localized immunosuppression (LIS) surrounding PN allografts as an alternative to systemically suppressing a patient's entire immune system. Methods include localized release of immunosuppressive (ISV) agents are contemplated in one embodiment. Methods also include localized application of immunosuppressive (ISV) regulatory T-cells (Tregs) in other embodiments. Hydrogel carrier materials for delivery of ISV agents and are also described herein.
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: June 16, 2020
    Assignee: UNIVERSITY OF WYOMING
    Inventor: Jared Bushman
  • Patent number: 10683257
    Abstract: The invention provides methods for synthesizing the compound (2R,3S,4E)-N-methyl-5-(4?-pentylphenyl)-2-aminopent-4-ene-1,3-diol, also known as SK1-I, and intermediate compounds used in its synthesis.
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: June 16, 2020
    Assignee: Enzo Biochem, Inc.
    Inventors: Zaiguo Li, Natarajan Raju, Praveen Pande
  • Patent number: 10610147
    Abstract: Systems and methods of the present invention provide for an olfactometer for delivering one or more odors and one or more computing devices configured to: receive user input for an odor memory test and an odor discrimination test; calculate a score for the odor memory test and the odor discrimination test; calculate a first and second confidence interval threshold and a second confidence interval threshold for a first and second predicted odor memory score respectively, based on a relationship between, respectively, the odor memory test score and odor discrimination test score, and previously-entered performance data queried from the database; and responsive to the score for the odor memory test not being greater than the first confidence interval threshold and the score for the odor discrimination test not being greater than the second confidence interval threshold, generate a report identifying a user as high risk for a neurodegenerative disease.
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: April 7, 2020
    Assignee: The General Hospital Corporation
    Inventor: Mark W. Albers
  • Patent number: 10604807
    Abstract: Methods are provided for assessing a clinical response to a glucocorticoid receptor antagonist (GRA) in a human subject and for diagnosing Cushing's syndrome.
    Type: Grant
    Filed: May 18, 2016
    Date of Patent: March 31, 2020
    Assignee: Corcept Therapeutics, Inc.
    Inventors: Joseph K. Belanoff, Hazel Hunt, John Francis Unitt, Andreas G. Moraitis
  • Patent number: 10595530
    Abstract: Methods of breaking down a biofilm or inhibiting, preventing or treating a microbial infection that produces a biofilm are disclosed, which involves administration of a polypeptide that has one or more HMG-box domains to a subject suffering from the infection or having the biofilm. By competing with microbial proteins that bind to DNA scaffold in the biofilm, these polypeptides destabilize the biofilm leading to destruction and removal of the biofilm by the immune system.
    Type: Grant
    Filed: October 16, 2015
    Date of Patent: March 24, 2020
    Assignees: Nationwide Children's Hospital, Inc., University of Southern California
    Inventors: Steven D. Goodman, Lauren O. Bakaletz
  • Patent number: 10578624
    Abstract: Detecting glycosaminoglycans (GAGs) and/or determining the level of one or more glycosaminoglycans can be useful, e.g., in identifying or monitoring various medical conditions, the status of patients having various medical conditions, and/or the response to treatment of individuals having various medical conditions. The present invention provides methods for detecting glycosaminoglycans and/or determining the level of glycosaminoglycans through the use of, e.g., mass spectrometry.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: March 3, 2020
    Assignee: Shire Human Genetic Therapies, Inc.
    Inventors: Hicham Naimy, Yongchang Qiu, Patrick Anthony John Haslett, Ann Barbier
  • Patent number: 10568822
    Abstract: Provided is a new application for D-pantothenyl alcohol. It is a melanogenesis inhibitor comprising D-pantothenyl alcohol.
    Type: Grant
    Filed: April 2, 2015
    Date of Patent: February 25, 2020
    Assignee: POLA CHEMICAL INDUSTRIES, INC.
    Inventors: Chihiro Kondo, Shoko Sassa, Yuko Saitoh, Yasuhito Mori, Kouji Yokoyama
  • Patent number: 10548993
    Abstract: Nanoparticles described as metal-encapsulated carbonaceous dots or M@C-dots are disclosed. Also disclosed are specific M@C-dots with gadolinium, so called Gd@C-dots. These nanoparticles are biologically inert and preclude the release of metal in biological environments. In addition, despite a dimension exceeding the commonly recognized threshold for renal clearance, the disclosed nanoparticles can be efficiently cleared via urine after systematic injection. Methods of making and using such nanoparticles are also disclosed.
    Type: Grant
    Filed: July 30, 2015
    Date of Patent: February 4, 2020
    Assignee: UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.
    Inventors: Jin Xie, Hongmin Chen, Geoffrey D. Wang
  • Patent number: 10550154
    Abstract: Disclosed are compositions and method related to variants of SPINK2 that bind to targets other than an endogenous target of SPINK2. In one embodiment, a peptide is provided that comprises the amino acid sequence SEQ ID NO: 1. In further embodiments, an amino acid sequences encoded by nucleotide positions 4 to 42 and/or nucleotide positions 94 to 189 in the nucleotide sequence of SEQ ID NO: 14 flank the amino terminus and the carboxyl terminus, respectively, of the amino acid sequence. In another embodiment, a peptide is provided that comprises an amino acid sequence derived from the amino acid sequence of SEQ ID NO: 1 in which a conservative substitution, deletion, addition and/or insertion of 1 to 5 (inclusive) amino acids has occurred at amino acids other than the 1st Xaa to the 12th Xaa counting from the amino terminus.
    Type: Grant
    Filed: August 7, 2013
    Date of Patent: February 4, 2020
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Daisuke Nishimiya, Ryuji Hashimoto
  • Patent number: 10538567
    Abstract: The present invention relates to trigonal GLP-1/glucagon/GIP receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: January 21, 2020
    Assignee: SANOFI
    Inventors: Martin Bossart, Andreas Evers, Torsten Haack, Dieter Kadereit, Katrin Lorenz, Michael Wagner, Stefania Pfeiffer-Marek, Martin Lorenz
  • Patent number: 10512689
    Abstract: This provides pharmaceutical compositions that comprise a combination of an anti-cancer agent which is an first antibody and a second antibody. In some embodiments, the first antibody is an anti-Programmed Death-1 (PD-1) antibody. In certain embodiments, the composition is a fixed dose formulation. In certain embodiments, the composition is administered as a flat-dose. The disclosure also provides a kit for treating a subject afflicted with a disease, the kit comprising a dosage of any composition disclosed herein and instructions for using the composition in any of the disclosed methods for treating a disease.
    Type: Grant
    Filed: November 30, 2016
    Date of Patent: December 24, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Vikram Sadineni, Yong Quan, Wallace Kaserer
  • Patent number: 10500178
    Abstract: Provided are therapeutic methods for treating a patient with lymphedema, or prophylactically treating an individual susceptible to lymphedema, by inhibiting synthesis activity of leukotriene B4.
    Type: Grant
    Filed: March 11, 2016
    Date of Patent: December 10, 2019
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Stanley G. Rockson, Mark R. Nicolls, Wen A. Tian, Xinguo Jiang, Jeanna Kim
  • Patent number: 10494610
    Abstract: Synthetic inert 3D gel culture systems are described that can be finely tuned to exhibit desired and predetermined physical, chemical, mechanical, and biochemical properties. The culture system can be utilized to study the effect of microenvironmental factors on cancer cell response, and in particular on cancer stem cell (CSC) response. Cancer cells can be encapsulated in a crosslinked gel system having a narrow range of predetermined gel stiffness. One or more biochemical factors including peptides that can affect the growth, development, and/or proliferation of CSCs can be incorporated in the system to examine the effects of the factor(s) on the encapsulated cells with regard to growth, proliferation, size, etc.
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: December 3, 2019
    Assignee: University of South Carolina
    Inventor: Esmaiel Jabbari
  • Patent number: 10494427
    Abstract: The application discloses a linear or substantially linear epitope on netrin-1 that likely corresponds to the specific binding region of netrin-1 to receptor, in particular of the UNC5 class, especially UNC5B and UNC5A, or alternatively corresponds to a region nearby the specific binding region of netrin-1 to receptor that when bound to an antibody prevents netrin-1/receptor interaction. This determination of a linear epitope allows the Applicant to produce antibodies binding to netrin-1 and interfering with netrin-1/receptor interaction, thereby inducing apoptosis or cell death of tumour cells expressing or overexpressing netrin-1 and at least one netrin-1 receptor, owing the fact that this interaction inhibits netrin-1 binding to a receptor and the multimerization of the receptor. The application discloses a murine monoclonal antibody directed against this epitope and various humanized forms thereof.
    Type: Grant
    Filed: January 9, 2015
    Date of Patent: December 3, 2019
    Assignee: NETRIS PHARMA
    Inventors: Jean-Guy Delcros, Yann Dean
  • Patent number: 10456416
    Abstract: Disclosed herein are compositions and methods to treat microbial infections and heal wounds. In some embodiments, the microbial infection may be a microbial biofilm. In some embodiments, the composition of the invention may include at least one surface active agent. The surface active agents may be anionic, cationic or non-ionic, or any combination thereof.
    Type: Grant
    Filed: January 20, 2016
    Date of Patent: October 29, 2019
    Assignee: Plurogen Therapeutics, LLC
    Inventors: Neal Koller, George Rodeheaver, John Bistline, Jr., Steven Coates
  • Patent number: 10458914
    Abstract: The invention described herein relates to a method of detecting malaria comprising the steps of: (i) delivering an evanescent IR beam through said ATR substrate in contact with a patient blood sample; (ii) detecting IR radiation transmitted from the ATR substrate to produce a signal characteristic for one or more lipids in the sample, and (iii) processing said signal and a set of reference library spectra of lipids associated with malaria parasites in order to detect matches and quantify said one or more lipids in the sample. In contrast to the prior art, the present invention relies on detecting lipids instead of hemozoin.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: October 29, 2019
    Assignees: Monash University, University of Melbourne
    Inventors: Bayden Robert Wood, Aazam Khoshmanesh, Matthew Dixon, Leann Tilley, Donald McNaughton
  • Patent number: 10450570
    Abstract: The invention relates to compositions and methods for reducing excessive vascular development and treat related disorders. In one aspect, the invention provides methods for treating, reducing or inhibiting vascular development in a subject in need thereof. The methods of the invention comprises administering to the subject an effective amount of a HK2 depleting agent that decreases the level of expression and/or activity of HK2. In some embodiments, the level of expression and/or activity of fibroblast growth factor receptor (FGFR), FGF ligand and/or FGF signaling is/are decreased. The invention also includes methods for diagnosing excessive vascular development and for measuring the efficacy of a treatment for an excessive vascular development in a subject in need thereof. The invention further includes a pharmaceutical composition for treating or reducing angiogenesis or lymphangiogenesis, comprising a HK2 depleting agent and a pharmaceutical acceptable carrier.
    Type: Grant
    Filed: December 4, 2017
    Date of Patent: October 22, 2019
    Assignee: Yale University
    Inventors: Michael Simons, Pengchun Yu
  • Patent number: 10377819
    Abstract: The present invention provides methods for treating and improving the symptoms of osteogenesis imperfecta (OI) in a subject by administering to the subject a therapeutically effective amount of a binding agent that binds to transforming growth factor beta (TGF?).
    Type: Grant
    Filed: February 8, 2017
    Date of Patent: August 13, 2019
    Assignees: GENZYME CORPORATION, Baylor College of Medicine
    Inventors: Brendan Lee, Kuber T. Sampath
  • Patent number: 10364211
    Abstract: The invention provides methods for synthesizing the compound (2R,3S,4E)-N-methyl-5-(4?-pentylphenyl)-2-aminopent-4-ene-1,3-diol, also known as SK1-I, and intermediate compounds used in its synthesis.
    Type: Grant
    Filed: October 24, 2018
    Date of Patent: July 30, 2019
    Assignee: Enzo Biochem, Inc.
    Inventors: Zaiguo Li, Natarajan Raju, Praveen Pande
  • Patent number: 10350184
    Abstract: This invention relates to oxime and alkoxy derivatives of the general formula (I), or an enantiomer, diastereoisomer, hydrate, solvate, tautomer, racemic mixture or pharmaceutically acceptable salt thereof for use as a medicament for the treatment and/or prevention of muscle atrophy in mammals and/or for limiting muscular atrophy in mammals and/or to promote muscle growth in exercising mammals aimed at increasing muscle mass and quality, preventing the occurrence of symptoms of sarcopenia related to age or rehabilitation after a muscle loss, age-related muscle atrophy and/or the consequences of drug therapy and/or immobilization and/or cachexia.
    Type: Grant
    Filed: April 14, 2016
    Date of Patent: July 16, 2019
    Assignee: METABRAIN RESEARCH
    Inventors: Sophie N. Raynal, Micheline R. Kergoat, Valerie Autier, Christine G. Charon, Jean-Denis Durand, Franck F. Lepifre, Annick M. Audet
  • Patent number: 10350273
    Abstract: The present invention refers to a GPR101 inhibitor, antagonist or inverse agonist or inverse agonist for use in preventive and/or therapeutic treatment of diseases selected from the group consisting of acromegaly and gigantism and to methods for preventive and/or therapeutic treatment of diseases selected from the group consisting of acromegaly and gigantism. Further, the present invention provides a GPR101 agonist for use in preventive and/or therapeutic treatment of disorders selected from the group consisting of dwarfism, short stature, hypopituitarism and a disease of low levels of pituitary hormone secretion and to methods for preventive and/or therapeutic treatment of diseases selected from the group consisting of dwarfism, short stature, hypopituitarism and a disease of low levels of pituitary hormone secretion wherein to a subject GPR101 agonist is administered.
    Type: Grant
    Filed: November 12, 2015
    Date of Patent: July 16, 2019
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Université de Liége and Centre Hospitalier Universitaire De Liége
    Inventors: Albert Beckers, Adrian Francis Daly, Fabio Rueda Faucz, Constantine A. Stratakis, Giampaolo Trivellin
  • Patent number: 10322125
    Abstract: This disclosure relates to compounds and compositions for cartilage repair and methods related thereto. In certain embodiments, the disclosure relates to methods of inducing cartilage growth and regeneration comprising administering an effective amount of a composition comprising a compound disclosed herein to the subject or implanting a cartilage matrix comprising a compound disclosed herein in the subject. In certain embodiments, the compound is used locally such as injection at any desired site of cartilage formation.
    Type: Grant
    Filed: February 18, 2014
    Date of Patent: June 18, 2019
    Assignees: Emory University, The United States of America as represented by the Department of Veteran Affairs
    Inventors: Scott D Boden, Sreedhara Sangadala